Joseph I. Clark

Loyola University Medical Center — United States

Medicine · Health Sciences

46h-index26.0kcitations173works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(65), Renal cell carcinoma treatment(46), CAR-T cell therapy research(37), Immunotherapy and Immune Responses(34), Cancer Genomics and Diagnostics(20)

Publications170 total

Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy
Journal of Investigative Medicine High Impact Case Reports·2025· 1 citedOpen Access
A Prospective, Multicenter Analysis of Recurrence‐Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31‐<scp>GEP</scp>
Cancer Medicine·2025· 2 citedOpen Access
P1026 Rectal stump surveillance in the IBD population
Journal of Crohn s and Colitis·2025· 1 citedOpen Access
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
European Urology·2024· 8 citedOpen Access
1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Annals of Oncology·2023Open Access
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
The Lancet·2023· 42 citedOpen Access
Implementing a cognitive behavioral intervention for patients with head and neck cancer
Supportive Care in Cancer·2023· 12 cited
Rare Columnar Cell Variant Papillary Thyroid Carcinoma with Metastasis to Pancreas and Lungs at Initial Presentation: A Case Report and Review of Literature
Journal of Gastrointestinal and Abdominal Radiology·2022Open Access
Longitudinal Outcomes From a Clinical Evaluation of a Cognitive- Behavioral Intervention for Patients With Head and Neck Cancer
2022Open Access
EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).
Journal of Clinical Oncology·2022· 39 cited
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective
Radiographics·2021· 79 cited
Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma—Are There Any Favorable Risk Patients?
The Journal of Urology·2021· 1 cited
Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2
Journal of Investigative Medicine·2021· 22 citedOpen Access
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells
Molecular Therapy — Oncolytics·2021· 10 citedOpen Access
52 Advanced T lymphocyte analysis system (ATLAS) for in-depth immunological interrogation in real-world conditions, a methodological strategy
Regular and Young Investigator Award Abstracts·2020· 1 citedOpen Access
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Nature Medicine·2020· 108 citedOpen Access
Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma
Cancer Research·2020· 5 cited
Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.
Journal of Clinical Oncology·2020· 1 cited
Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
Journal for ImmunoTherapy of Cancer·2020Open Access
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
Frontiers in Oncology·2020· 11 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Kim Margolin(14), Michael B. Atkins(14), Jeffrey A. Sosman(13), Janice P. Dutcher(13), David F. McDermott(10), Marc S. Ernstoff(10), Theodore F. Logan(9), Geoffrey R. Weiss(8), Brendan D. Curti(7), Walter J. Urba(6), John M. Kirkwood(6), Howard L. Kaufman(6), René González(5), James W. Mier(5), F. Stephen Hodi(4), Jose Lutzky(4), Lawrence E. Flaherty(4), Michael S. Gordon(4), John W. Smith(4), Robert C. Flanigan(4)